But when that process goes awry, leading to uncontrolled cell growth, cancer can emerge. New CU Boulder research, published in the journal Science Advances, offers unprecedented insight into how an ...

However, CDK4/6 inhibitors have their limitations. Many tumors develop resistance by switching to alternative CDK pathways, pushing for the next-generation CDK inhibitors to target CDK2, CDK7, and ...

New research offers unprecedented insight into how an enigmatic enzyme, known as CDK7, drives the cell cycle and cell proliferation. For organs to develop, grow and regenerate, cells must proliferate.

For decades, cancer researchers and pharmaceutical companies have eyed cyclin-dependent kinase (CDK7) with interest due to its role as a "master regulator" of cell proliferation. CDK7 does this in ...

New CU Boulder research, published in the journal Science Advances, offers unprecedented insight into how an enigmatic enzyme, known as CDK7, drives this complex process. The research shows that ...